csirt@kutim:~/threat-intel/cve/CVE-2023-20019

Katalog CVE

CVSS 6.1 · Medium EPSS 0,59%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') pada cisco broadworks application delivery platform, cisco broadworks application server +1 lainnya. Skor CVSS 3.1 6.1 (Medium) menurut NVD.

Deskripsi (NVD)

A vulnerability in the web-based management interface of Cisco BroadWorks Application Delivery Platform, Cisco BroadWorks Application Server, and Cisco BroadWorks Xtended Services Platform could allow an unauthenticated, remote attacker to conduct a cross-site scripting (XSS) attack against a user of the interface of an affected device. This vulnerability exists because the web-based management interface does not properly validate user-supplied input. An attacker could exploit this vulnerability by persuading a user of the interface to click a crafted link. A successful exploit could allow the attacker to execute arbitrary script code in the context of the affected interface or access sensitive, browser-based information.

Rincian

Terbit di NVD
20 Januari 2023
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
6.1 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,59% peluang dieksploitasi; lebih tinggi dari 46,6% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
cisco broadworks application delivery platform Semua versi sebelum commpilot-24_2022.11
cisco broadworks application server Semua versi sebelum ap.as.24.0.944.ap384344
cisco broadworks xtended services platform Semua versi sebelum ap.xsp.23.0.1075.ap384344

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.